People living with rheumatoid arthritis (RA) often feel misunderstood, according to findings from Rheumatoid Arthritis In America 2018, an annual research study conducted by Health Union. The study of 3,181 respondents illuminates the realities about why it may be so misunderstood.
The intensity and severity of flares experienced by people living with plaque psoriasis (Pso) and psoriatic arthritis (PsA) may not be getting the attention they deserve as evidenced by the latest results of Health Union’s Psoriasis In America and Psoriatic Arthritis In America 2018 surveys.
Download the whitepaper, “Patient Experience in Clinical Trials,” which analyzes differences in the perceptions of those who have participated in a clinical trial in the last five years to those participants prior to 2013, and how to dispel the myths that exist in the industry by looking through a true patient-centric lens.
Think for a moment how a car simply can’t run without both gasoline and oil. You can’t really argue which one is more important because that doesn’t matter: without either, the car won’t go. Everything in our business works like gas and oil in a car: because each individual understands that, no matter their role, what they do is crucial to our success.
Debilitating. Frustrating. Devastating. When asked to describe their condition in one word, COPD patients’ choice of words reveals struggle, fear, misery, and helplessness in Health Union’s COPD In America 2018 survey.
For many people living with multiple sclerosis (MS), treatment decisions can often be nuanced and complicated. In April of 2018, the American Academy of Neurology (AAN) released new guidelines about when to begin, change, and end disease-modifying therapies (DMTs) for MS patients. MS In America 2018 results may help the healthcare industry gain a broader understanding of people’s experiences, or lack thereof, with DMTs and other MS treatment options.
Download the full free whitepaper, “#authenticity How Social Media Can Fuel Growth-Oriented, Sustainable Online Communities”
There is a lot of talk in the industry about patient centricity, but is it the reality? We talk about putting the needs of patients first and keeping them central in the business decisions we make across the healthcare industry. However, as we discussed on a panel at this year’s DIA 2018 Global Annual Meeting, somehow in the effort to amplify patient centricity, a critical voice is often underrepresented—the voice of the patient.
A new class of migraine drugs, called anti-CGRPs (calcitonin gene-related peptide) are expected to reinvigorate a market that has been largely dormant for some time. Four biopharma companies, Amgen, Teva, Lilly and Alder are entering the fray. Not surprisingly, the intense competition and pharma investment associated with this market dynamic has led traditional “eyeball driven” publishers, like WebMD, Everyday Health and others on a quest to offer substantially more migraine-related content in reaction to this market opportunity.
“Asthma In America 2018” asked questions about diagnosis, medications, treatments and more to over 800 respondents. Surprisingly, the survey revealed four things people with asthma fear most about their future, all of which have a profound impact on the way they view their condition and rate their quality of life.
1218 Chestnut St., 3rd Floor
Philadelphia, PA 19107
Phone: 484-985-9715
Fax: 484-450-2513
Privacy Notice
Terms of Use
Your Privacy Choices 
Join Our Team
Press Kit